104 related articles for article (PubMed ID: 25573518)
1. Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma.
Yi B; Zhang Y; Zhu D; Zhang L; Song S; He S; Zhang B; Li D; Zhou J
Oncol Rep; 2015 Mar; 33(3):1201-6. PubMed ID: 25573518
[TBL] [Abstract][Full Text] [Related]
2. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.
Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D
Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627
[TBL] [Abstract][Full Text] [Related]
3. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
Fang Y; Yi J; Lizhi L; Qiucheng C
DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma.
Li X; Wang J; Zhang X; Zeng Y; Liang L; Ding Y
Ann Surg Oncol; 2012 Jan; 19(1):145-53. PubMed ID: 21861235
[TBL] [Abstract][Full Text] [Related]
5. RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.
Cho HJ; Park SM; Kim IK; Nam IK; Baek KE; Im MJ; Yoo JM; Park SH; Ryu KJ; Han HT; Kim HJ; Hong SC; Kim KD; Pak Y; Kim JW; Lee CW; Yoo J
Oncotarget; 2014 Mar; 5(6):1554-64. PubMed ID: 24721928
[TBL] [Abstract][Full Text] [Related]
6. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway.
Zhang M; Ding G; Zhou L; Shen T; Xu X; Zhao T; Jia S; Cao L
J Interferon Cytokine Res; 2018 Sep; 38(9):413-422. PubMed ID: 30192158
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of Rho GDP dissociation inhibitor 2 in colorectal carcinoma.
Fujita A; Shida A; Fujioka S; Kurihara H; Okamoto T; Yanaga K
Int J Clin Oncol; 2012 Apr; 17(2):137-42. PubMed ID: 21698524
[TBL] [Abstract][Full Text] [Related]
8. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression.
Yi B; Hu Y; Zhu D; Yao J; Zhou J; Zhang Y; He Z; Zhang L; Zhang Z; Yang J; Tang Y; Huang Y; Li D; Liu Q
Genes Genomics; 2022 May; 44(5):561-569. PubMed ID: 35147897
[TBL] [Abstract][Full Text] [Related]
9. TAT-RhoGDI2, a novel tumor metastasis suppressor fusion protein: expression, purification and functional evaluation.
Xu R; Dong Y; Wang L; Tao X; Sun A; Wei D
Appl Microbiol Biotechnol; 2014 Dec; 98(23):9633-41. PubMed ID: 25142698
[TBL] [Abstract][Full Text] [Related]
10. RhoGDI2 is expressed in human trophoblasts and involved in their migration by inhibiting the activation of RAC1.
Liu S; Cui H; Li Q; Zhang L; Na Q; Liu C
Biol Reprod; 2014 Apr; 90(4):88. PubMed ID: 24554735
[TBL] [Abstract][Full Text] [Related]
11. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
12. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
13. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis.
Hu LD; Zou HF; Zhan SX; Cao KM
Oncol Rep; 2007 Jun; 17(6):1383-9. PubMed ID: 17487395
[TBL] [Abstract][Full Text] [Related]
14. p85-RhoGDI2, a novel complex, is required for PSGL-1-induced β1 integrin-mediated lymphocyte adhesion to VCAM-1.
Luo J; Xu T; Li C; Ba X; Wang X; Jiang Y; Zeng X
Int J Biochem Cell Biol; 2013 Dec; 45(12):2764-73. PubMed ID: 24055812
[TBL] [Abstract][Full Text] [Related]
15. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.
Griner EM; Dancik GM; Costello JC; Owens C; Guin S; Edwards MG; Brautigan DL; Theodorescu D
Mol Cancer Res; 2015 Mar; 13(3):483-92. PubMed ID: 25516960
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
17. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.
Ahmed M; Sottnik JL; Dancik GM; Sahu D; Hansel DE; Theodorescu D; Schwartz MA
Cancer Cell; 2016 Sep; 30(3):432-443. PubMed ID: 27593345
[TBL] [Abstract][Full Text] [Related]
18. RhoGDI2 as a therapeutic target in cancer.
Cho HJ; Baek KE; Yoo J
Expert Opin Ther Targets; 2010 Jan; 14(1):67-75. PubMed ID: 20001211
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer.
Xu L; Jiang Y; Zheng J; Xie G; Li J; Shi L; Fan S
Hum Pathol; 2013 Jul; 44(7):1357-64. PubMed ID: 23375645
[TBL] [Abstract][Full Text] [Related]
20. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
Wu Y; McRoberts K; Berr SS; Frierson HF; Conaway M; Theodorescu D
Oncogene; 2007 Feb; 26(5):765-73. PubMed ID: 16878152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
